Login
$BLLN
$96.50 +$0.19 (0.2%) After hours

$BLLN 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results f...

05 Aug 2026 8-K: Results of Operations and Financial Condition

MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for...

29 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On June 23, 2026, BillionToOne, Inc. (the “Company”) entered into a lease (the “Lease”) with Whipple Road Portfolio, LLC (the “Landlord”), pursuant to which the Company will lease approximately 62,659 square feet of office and laboratory...

16 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On June 10, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive...

06 May 2026 8-K: Results of Operations and Financial Condition

MENLO PARK, CA, May 6, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for th...

04 Mar 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

MENLO PARK, CA, March 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for ...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MENLO PARK, CA, January 12, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 gu...

09 Dec 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

MENLO PARK, CA, December 9, 2025 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results f...

10 Nov 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

Section 1.1 Annual Meetings. If required by applicable law or as otherwise determined by the Board of Directors (the “Board”) of BillionToOne, Inc. (the “Corporation”), an annual meeting of stockholders shall be held for the election of ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support